Meguro Satoru, Makabe Syunta, Yaginuma Kei, Onagi Akifumi, Tanji Ryo, Matsuoka Kanako, Hoshi Seiji, Koguchi Tomoyuki, Kayama Emina, Hata Junya, Sato Yuichi, Akaihata Hidenori, Kataoka Masao, Ogawa Soichiro, Uemura Motohide, Kojima Yoshiyuki
Department of Urology, School of Medicine, Fukushima Medical University, 1 Hikarigaoka, Fukushima 960-1295, Japan.
Curr Oncol. 2025 Aug 18;32(8):467. doi: 10.3390/curroncol32080467.
Since cancer is often linked to the aging process, the importance of cellular senescence in cancer has come under the spotlight. While senescence in cancer cells can serve as a natural barrier against cancer due to its proliferation arrest, its secretory phenotypes and alterations in the surface proteome can paradoxically promote or suppress tumor progression. Senescent cancer-associated fibroblasts, endothelial cells, and immune cells can also contribute to cancer promotion. During therapeutic interventions for cancer, not only their therapeutic effects, but also therapy-induced senescence may have an impact on cancer outcomes. Senotherapeutics, therapy targeting senescent cells, have been reported as novel cancer therapy in recent studies, and the combination of senescence induction and senotherapeutics has been increasingly recognized. Although some clinical trials of senotherapeutic drugs for cancer with or without senescence-inducible therapy are ongoing, there is as yet no satisfactory clinical application. With further research into targeting senescence in oncology, it is expected that senotherapeutics, particularly in combination with senescence-inducing therapy, will become a novel therapeutic strategy.
由于癌症常与衰老过程相关联，细胞衰老在癌症中的重要性已受到关注。虽然癌细胞中的衰老因其增殖停滞可作为对抗癌症的天然屏障，但其分泌表型和表面蛋白质组的改变却可能反常地促进或抑制肿瘤进展。衰老的癌症相关成纤维细胞、内皮细胞和免疫细胞也可促进癌症发展。在癌症治疗干预期间，不仅其治疗效果，而且治疗诱导的衰老可能会影响癌症结局。衰老疗法，即针对衰老细胞的疗法，在最近的研究中已被报道为一种新型癌症疗法，并且衰老诱导与衰老疗法的联合应用已得到越来越多的认可。尽管一些针对癌症的衰老治疗药物的临床试验，无论有无衰老诱导疗法，正在进行中，但目前尚无令人满意的临床应用。随着肿瘤学中针对衰老的进一步研究，预计衰老疗法，特别是与衰老诱导疗法联合应用时，将成为一种新型治疗策略。
